Sherry Kuo, DO
Pulmonary Disease · Grand Rapids, MINPI 1184839011
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 91.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $13,756 and has fallen 97.1% since, to $399 in 2025. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $226.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$27K
- GSK$549
- Boehringer Ingelheim$375
- Actelion Pharmaceuticals US, Inc.$368
- Grifols USA, LLC$273
- Sanofi$239
- plus $892 from 12 others
What the payments were for
- Consulting fees$7,99326%
- Speaking & faculty fees$16,30054%
- Travel & lodging$2,2097%
- Food & beverage$3,56112%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $27,467 |
| GSK | 7 | $549 |
| Boehringer Ingelheim | 16 | $375 |
| Actelion Pharmaceuticals US, Inc. | 10 | $368 |
| Grifols USA, LLC | 7 | $273 |
| Sanofi | 8 | $239 |
| Regeneron Healthcare Solutions, Inc. | 6 | $224 |
| Insmed, Inc. | 1 | $140 |
| Amgen | 1 | $118 |
| United Therapeutics Corporation | 2 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech, Inc. | 1 | $59 |
| Bayer | 2 | $37 |
| Verona Pharma, Inc. | 1 | $29 |
| Mylan Specialty L.p. | 2 | $27 |
| Genentech USA, Inc. | 1 | $21 |
| Breas Medical, Inc. | 1 | $17 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$16,493
- TAGRISSO$4,278
- FASENRA$843
- ANORO ELLIPTA$450
- DUPIXENT$250
- TEZSPIRE$237
- UPTRAVI$126
- OPSUMIT$126
- IMFINZI$125
- Prolastin-C$121
How this compares
$30,163 in reported general payments places this provider in the 90th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 343 | $262,515 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 265 | $211,569 |
| OfevNintedanib Esylate | 14 | $161,573 |
| TezspireTezepelumab-Ekko | 22 | $85,766 |
| Spiriva RespimatTiotropium Bromide | 36 | $28,049 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $20,057 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $17,179 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 98 | $15,420 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $13,973 |
| DuleraMometasone/Formoterol | 19 | $13,147 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 26 | $12,732 |
| Qvar RedihalerBeclomethasone Dipropionate | 33 | $9,487 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,916 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 244 | $8,499 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $7,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Symbicort, Pulmicort Flexhaler | $27,467 | $317,970338 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $549 | $296,449407 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $375 | $209,67996 claims |
| MerckDulera | $16 | $13,14719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Grand Rapids
- Gustavo Cumbo NacheliGrand Rapids$724K
- Reda GirgisGrand Rapids$61K
- Ashley ScottGrand Rapids$30K
- Anupam KumarGrand Rapids$29K
- Maria Katrina AbrilGrand Rapids$21K
- Paul HarrisGrand Rapids$20K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.